Hepatitis Drug Development Pipeline Review 2018 - Abivax, AiCuris, AIMM Therapeutics, Akshaya Bio, Alnylam Pharmaceuticals, Altimmune, Altravax

Hepatitis Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features dormant and discontinued products.

Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Hepatitis A and E are typically caused by ingestion of contaminated food or water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes.

Get More Information Download Sample Copy at https://www.premiummarketinsights.com/sample/GBI00004591?source=OpenPR-HM

Risk factors include a weakened immune system and use of injected or non-injected illicit drugs. Symptoms of hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite and pain in the abdomen.

Hepatitis B and hepatitis D infection typically occur as a result of contact with infected body fluids. Transmission of hepatitis B can occur via sexual contact, injection drug use or transfusions of contaminated blood and blood products. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting and abdominal pain.

Hepatitis D infection only occurs in persons previously infected with hepatitis B, as the hepatitis D virus can only replicate in the presence of hepatitis B. The co-infection of hepatitis B and hepatitis D is associated with greater disease severity than hepatitis B infection alone.

Companies operating in this pipeline space include Cadila Healthcare and Chongqing Zhifei Biological Products.

Scope

-Which companies are the most active within each pipeline-
-Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication-
-To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies-
-What are the most important R&D milestones and data publications to have happened in this disease area-

Reasons to buy

-Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
-Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
-Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
-Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Inquire Before Buying at https://www.premiummarketinsights.com/inquiry/GBI00004591?source=OpenPR-HM

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Hepatitis Report Coverage 8
2.2 Hepatitis A-Overview 8
2.3 Hepatitis B-Overview 8
2.4 Hepatitis D-Overview 8
2.5 Hepatitis E-Overview 8
3 Therapeutics Development 9
3.1 Hepatitis A 9
3.2 Hepatitis B 12
3.3 Hepatitis D 27
3.4 Hepatitis E 30
4 Therapeutics Assessment 33
4.1 Hepatitis A 33
4.2 Hepatitis B 35
4.3 Hepatitis D 44
4.4 Hepatitis E 49
5 Companies Involved in Therapeutics Development 52
5.1 Hepatitis A 52
5.2 Hepatitis B 54
5.3 Hepatitis D 95
5.4 Hepatitis E 98
6 Dormant Projects 101
6.1 Hepatitis A 101
6.2 Hepatitis B 102
6.3 Hepatitis D 108
6.4 Hepatitis E 108
7 Discontinued Products 109
7.1 Hepatitis B 109
8 Product Development Milestones 110
8.1 Hepatitis B 110
8.2 Hepatitis D 122
8.3 Hepatitis E 131
9 Appendix 132
9.1 Methodology 132
9.2 Coverage 132
9.3 Secondary Research 132
9.4 Primary Research 132
9.5 Expert Panel Validation 132
9.6 Contact Us 133
9.7 Disclaimer 133

Purchase this Premium Research Report at https://www.premiummarketinsights.com/buy/GBI00004591

Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.

Pune, India

This release was published on openPR.